<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>DIA | CSE Tracker</title>
    <link>/tag/20210627dia/</link>
      <atom:link href="/tag/20210627dia/index.xml" rel="self" type="application/rss+xml" />
    <description>DIA</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Sun, 27 Jun 2021 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hua2ec155b4296a9c9791d015323e16eb5_11927_512x512_fill_lanczos_center_2.png</url>
      <title>DIA</title>
      <link>/tag/20210627dia/</link>
    </image>
    
    <item>
      <title>DIA 2021 Global Annual Meeting</title>
      <link>/conference/20210627dia-2021-global-annual-meeting/</link>
      <pubDate>Sun, 27 Jun 2021 00:00:00 +0000</pubDate>
      <guid>/conference/20210627dia-2021-global-annual-meeting/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Estimands and Analysis Considerations for Clinical Trials Impacted by COVID-19</title>
      <link>/webinar/20200716estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19/</link>
      <pubDate>Thu, 16 Jul 2020 08:00:00 -0700</pubDate>
      <guid>/webinar/20200716estimands-and-analysis-considerations-for-clinical-trials-impacted-by-covid-19/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;The use of the estimand framework to assess and address pandemic-related disruptions&lt;/li&gt;
&lt;li&gt;Analysis strategies for pandemic-related missing and unobservable values&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
    <item>
      <title>COVID-19: Pandemic Preparedness and Lessons Learned</title>
      <link>/webinar/20200610dia/</link>
      <pubDate>Wed, 10 Jun 2020 00:00:00 +0000</pubDate>
      <guid>/webinar/20200610dia/</guid>
      <description>&lt;ul&gt;
&lt;li&gt;An overview of how COVID-19 progressed&lt;/li&gt;
&lt;li&gt;How can pharmaceutical companies be better prepared? Should there be plans and clinical development strategies in place?&lt;/li&gt;
&lt;li&gt;How do we build resiliency? What steps could/should be implemented at various stages to ‘flatten the curve’?&lt;/li&gt;
&lt;li&gt;Vulnerable communities and minority populations are at a disadvantage. How do we address these health disparities?&lt;/li&gt;
&lt;/ul&gt;</description>
    </item>
    
  </channel>
</rss>
